ArticleGlobal health, science and practice2018
Rapid Uptake of the Subcutaneous Injectable in Burkina Faso: Evidence From PMA2020 Cross-Sectional Surveys.
Article in Global health, science and practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- What Distinguishes Women Who Choose to Self-Inject? A Prospective Cohort Study of Subcutaneous Depot Medroxyprogesterone Acetate Users in Ghana.Global health, science and practice · 2022Article
- DMPA-SC stock: Cross-site trends by facility type.Contraception: X · 2022Article
- Characteristics associated with use of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Burkina Faso, Democratic Republic of Congo, and Uganda.Contraception: X · 2021Article
- Trends in subcutaneous depot medroxyprogesterone acetate (DMPA-SC) use in Burkina Faso, the Democratic Republic of Congo and Uganda.Contraception: X · 2019Article
- Evaluation of a pilot program for task sharing short and long-acting contraceptive methods in Burkina Faso.Gates open research · 2019Article
- Article
- The Coming-of-Age of Subcutaneous Injectable Contraception.Global health, science and practice · 2018Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The subcutaneous (SC) injectable, widely known by its commercial name Sayana Press, has potential to improve access to contraceptive methods. In Burkina Faso, SC-injectables were first piloted in select regions in 2014 and introduced nationally in 2016. PMA2020 is the first national survey to track programmatic progress of SC-injectable introduction at both population and health facility levels in the country across 2 rounds of data collection: March-May 2016 and November 2016-January 2017. Over this 6-month period, SC-injectable availability at public service delivery points increased from 50% to 85%, largely driven by increases in availability among the non-pilot regions. In terms of use, while the modern contraceptive prevalence rate among all women remained constant at about 23%, SC-injectable prevalence nearly doubled from 1.1% to 2.0%, making up approximately 9% of all modern method users in Burkina Faso by late 2016, though the difference was not statistically significant. Increases were comparable between pilot and non-pilot regions. While the difference was not statistically significant, more rural women were using the method compared with their urban counterparts in the pilot regions, an interesting finding considering the opposite pattern is generally true for contraceptive prevalence nationally. In summary, following national scale-up, data show substantially improved availability of SC-injectables at service delivery points and potential for changes in the method mix in Burkina Faso. In order to further improve contraceptive access and choice, scale-up of community-based distribution of SC-injectables should be considered, especially among rural populations with higher unmet need for family planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.